Skip to content
RKWD
ROCKWOOD RESEARCH · A CORPORATE FILINGS WEBSITE|STRAIGHT FROM THE SOURCE · SEC EDGAR|SPONSOREDYour message on this tape — bid on the Rockwood Ad Exchange · Rockwood Ad Exchange|
Rockwood Research
…

TARA

Protara Therapeutics, Inc.

Biological Products, (No Diagnostic Substances) · SIC 2836CIK 1359931Held by 2 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:XLINKEDINEMAIL
Revenue FY2025
—
Net Income FY2025
$(57.0M)
EPS (Basic, as reported)
$-1.34
Net Margin FY2025
—
ROE FY2025
-29.2%
Total Equity
$196.0M
Shares Out
59M
Business description

Protara Therapeutics, Inc. — Biological Products, (No Diagnostic Substances). Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2012–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions
i
default rows · click any row to chart itNet income: (29) → (57)
Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023⚑FY2024⚑FY2025
Revenue——————————
Research & development(19)(22)(12)(6)(12)(21)(17)(25)(32)(43)
General & administrative(10)(9)(10)(9)(22)(26)(21)(19)(17)(22)
Total operating expenses(29)(30)(21)(15)(34)(47)(67)(44)(49)(65)
Operating income(29)(30)(21)(15)(34)(47)(67)(44)(49)(65)
Interest expense————00————
Interest & investment income————101346
Other income (expense), net0010001357
Pre-tax income(29)(30)(21)(15)————4557
Income tax expense——————————
Net income(29)(30)(21)(15)(34)(47)(66)(40)(45)(57)
EPS — basic—————($4.21)($5.86)($3.57)($2.17)($1.34)
EPS — diluted—————($4.21)($5.86)($3.57)($2.17)($1.34)
Shares outstanding — basic (M)——————11112143
Shares outstanding — diluted (M)—————1111112143

Showing the latest 10 of 14 fiscal years.

  • ⚑ Weighted-average shares changed ×1.91 between FY2023 and FY2024 — likely a stock split. Per-share figures on either side are as reported and not adjusted.
  • ⚑ Weighted-average shares changed ×2.05 between FY2024 and FY2025 — likely a stock split. Per-share figures on either side are as reported and not adjusted.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.